MovDisordV3, PascalFrancis, Corpus, bibRecord, 001829

Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Identifieur interne : 001829 ( PascalFrancis/Corpus ); précédent : 001828; suivant : 001830

Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Auteurs : Anthony P. Nicholas

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0133223

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Dyskinésie, Parkinson maladie, Lévodopa, Hyperactivité, Animal, Souris, Traitement.

English descriptors

KwdEn :
- Animal, Dyskinesia, Hyperactivity, Levodopa, Mouse, Nervous system diseases, Parkinson disease, Treatment.

Abstract

The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine`
A11	`01`	`1`		`@1 NICHOLAS (Anthony P.)`
A14	`01`			`@1 Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center @2 Birmingham, Alabama @3 USA @Z 1 aut.`
A20				`@1 99-104`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000145483830140`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 54 ref.`
A47	`01`	`1`		`@0 07-0133223`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C02	`03`	`X`		`@0 002B17G`
C02	`04`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Hyperactivité @5 10`
C03	`05`	`X`	`ENG`	`@0 Hyperactivity @5 10`
C03	`05`	`X`	`SPA`	`@0 Hiperactividad @5 10`
C03	`06`	`X`	`FRE`	`@0 Animal @5 11`
C03	`06`	`X`	`ENG`	`@0 Animal @5 11`
C03	`06`	`X`	`SPA`	`@0 Animal @5 11`
C03	`07`	`X`	`FRE`	`@0 Souris @5 12`
C03	`07`	`X`	`ENG`	`@0 Mouse @5 12`
C03	`07`	`X`	`SPA`	`@0 Ratón @5 12`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 13`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 13`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 13`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 37`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`05`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`05`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`05`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 39`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 39`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 39`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 40`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`09`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 42`
C07	`09`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`09`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
N21				`@1 085`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0133223 INIST
ET :	Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine
AU :	NICHOLAS (Anthony P.)
AF :	Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center/Birmingham, Alabama/Etats-Unis (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 1; Pp. 99-104; Bibl. 54 ref.
LA :	Anglais
EA :	The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.
CC :	002B17; 002B02U01; 002B17G; 002B02B06
FD :	Système nerveux pathologie; Dyskinésie; Parkinson maladie; Lévodopa; Hyperactivité; Animal; Souris; Traitement
FG :	Rodentia; Mammalia; Vertebrata; Extrapyramidal syndrome; Mouvement involontaire; Trouble neurologique; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Dyskinesia; Parkinson disease; Levodopa; Hyperactivity; Animal; Mouse; Treatment
EG :	Rodentia; Mammalia; Vertebrata; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Disquinesia; Parkinson enfermedad; Levodopa; Hiperactividad; Animal; Ratón; Tratamiento
LO :	INIST-20953.354000145483830140
ID :	07-0133223

Links to Exploration step

Pascal:07-0133223

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine</title>
<author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0133223</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0133223 INIST</idno>
<idno type="RBID">Pascal:07-0133223</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001829</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine</title>
<author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Dyskinesia</term>
<term>Hyperactivity</term>
<term>Levodopa</term>
<term>Mouse</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dyskinésie</term>
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Hyperactivité</term>
<term>Animal</term>
<term>Souris</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NICHOLAS (Anthony P.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>99-104</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000145483830140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>54 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0133223</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="04" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Hyperactivité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hyperactivity</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hiperactividad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Souris</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mouse</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ratón</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fN21><s1>085</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0133223 INIST</NO>
<ET>Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine</ET>
<AU>NICHOLAS (Anthony P.)</AU>
<AF>Department of Neurology, University of Alabama at Birmingham and the Birmingham Veterans Administration Medical Center/Birmingham, Alabama/Etats-Unis (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 1; Pp. 99-104; Bibl. 54 ref.</SO>
<LA>Anglais</LA>
<EA>The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/kg) plus carbidopa (25 mg/kg). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP.</EA>
<CC>002B17; 002B02U01; 002B17G; 002B02B06</CC>
<FD>Système nerveux pathologie; Dyskinésie; Parkinson maladie; Lévodopa; Hyperactivité; Animal; Souris; Traitement</FD>
<FG>Rodentia; Mammalia; Vertebrata; Extrapyramidal syndrome; Mouvement involontaire; Trouble neurologique; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Dyskinesia; Parkinson disease; Levodopa; Hyperactivity; Animal; Mouse; Treatment</ED>
<EG>Rodentia; Mammalia; Vertebrata; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Disquinesia; Parkinson enfermedad; Levodopa; Hiperactividad; Animal; Ratón; Tratamiento</SD>
<LO>INIST-20953.354000145483830140</LO>
<ID>07-0133223</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001829 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001829 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0133223
   |texte=   Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri